Today's HAI Medical (02225): Join hands with China Pharmaceutical Lingshang to accelerate the commercialization process of high-end medical devices.

In the medical device industry, innovation is the core driving force for technological advancement, but even the best products need commercialization to realize their value. As a leading player in the high-end endoscope field in China, Jinhai Medical (02225) not only continues to lead in the 4K3D fluorescence composite endoscope field, but also demonstrates strong development momentum in other high-end medical equipment. In order to further enhance the company's position in the domestic and international markets, Jinhai Medical has accelerated the commercialization of its flagship products through the establishment of a commercialization team and external cooperation. Joining forces with Sinopharm Commercial, promoting domestic high-end medical devices to a new level It is understood that on January 3, 2025, Jinhai Medical announced that its subsidiary Jinhai Xiehuan Medical reached a commercial cooperation with Sinopharm Commercial, authorizing Sinopharm Commercial as the exclusive distributor of the company's high-end medical devices in China. This partnership basically covers Jinhai Medical's flagship products, including 4K3D fluorescence composite endoscopes, intervertebral foramen scopes, and a series of advanced instrument kits. Public information shows that Sinopharm Commercial is a subsidiary of China Meheco Group, jointly invested by SINOPHARM Corporation and Mitsubishi Corporation of Japan. As a medical consumables integrated operation service provider, Sinopharm Commercial is committed to building a digitalized supply chain service platform based on big data and interconnected information systems to provide customers with end-to-end supply chain solutions. In addition, Sinopharm Commercial also has diversified business models to meet diverse and personalized market needs, such as commissioned distribution, direct sales promotion, and nationwide distribution. Relying on Sinopharm Commercial's extensive channel advantages and strong market influence, Jinhai Medical's flagship products can quickly cover a wider market and achieve rapid growth. In particular, with the advancement of the domestication process of high-end medical equipment, Jinhai Medical's 4K3D fluorescence endoscopes, intervertebral foramen scopes, and supporting instrument kits have shown strong market competitiveness and growth potential. Cooperation with Sinopharm Commercial will undoubtedly further consolidate and expand the market share of these products. For Jinhai Medical, this cooperation with Sinopharm Commercial marks an important step in its business development, a result of Jinhai Medical's continuous deep cultivation in the medical technology field, and also means that the company has been recognized by a super large platform in the industry. For Sinopharm Commercial, cooperation with an enterprise like Jinhai Medical with strong technological innovation capabilities will help to achieve complementary advantages of technology and resources, jointly promote the research and development and market promotion of medical technology products. Therefore, the cooperation between Jinhai Medical and Sinopharm Commercial is not only the beginning of mutual resource sharing and complementary advantages, but also heralds that Jinhai Medical will gain more extensive recognition in the field of medical technology. With the deepening of cooperation, Jinhai Medical is expected to achieve more cooperation intentions and open a new chapter of business development. This collaboration is not only significant for both companies, but will also have a positive impact on the entire medical technology industry, promoting innovation in collaboration models and overall service level enhancement. It is worth mentioning that Sinopharm Commercial has cooperation with the Private Hospitals Association of Malaysia, so cooperation with Sinopharm Commercial will help Jinhai Medical's products to enter a broader international market in the future, providing opportunities for Jinhai Medical's products to go overseas. In addition to cooperation with Sinopharm Commercial, Jinhai Medical is also actively establishing a commercial team, appointing veteran He Xiao with over ten years of medical sales experience as Chief Marketing Officer, responsible for formulating and implementing the company's marketing strategy and sales objectives, sales channel promotion and management. With its rich resources in the medical industry, Jinhai Medical's commercialization pace is expected to accelerate. In addition, in order to better serve customers, Jinhai Medical also plans to establish four sales centers. Through external cooperation and the establishment of its own commercialization team, it can be foreseen that in the near future, Jinhai Medical's level of commercialization will make a qualitative leap, and the company's performance is expected to achieve explosive growth. With a variety of products under research, performance is expected to continue to achieve high growth It is worth mentioning that in the first half of this year, Jinhai Medical's performance has already shown signs of high growth. It is understood that in the first half of this year, Jinhai Medical achieved revenue of 25.937 million Singapore dollars, an increase of 116.45% year-on-year. Among them, revenue from minimally invasive surgical solutions and medical products and related service fees increased from 400,000 Singapore dollars in the first half of 2023 to 12.3 million Singapore dollars in the first half of 2024. Although revenue from minimally invasive surgical products has increased significantly, Jinhai Medical's registration certificate for 4K3D fluorescence endoscopes was not approved until the third quarter of this year. Therefore, with the push of this product, Jinhai Medical is expected to achieve a sustained high-growth trend in the third and fourth quarters. In addition to the products already on the market, relying on its deep accumulation in the field of endoscope technology, Jinhai Medical is entering the field of intervertebral foramen scopes and minimally invasive spine, promising to create a second growth curve for Jinhai Medical. In terms of technological reserves, Jinhai Medical has more than 60 patents, over 20 trademarks, and over 30 projects under research. In the "minimally invasive 4.0 era", Jinhai Medical's basic technology is fully leading, with existing technologies including three/four chips, naked eye 3D, 4K, 3D, and fluorescence. In the current rapid development of AI, Jinhai Medical is also actively promoting the research and development of technology towards "minimally invasive 5.0". In the future, the company will focus on molecular probes, multispectral, intelligent navigation, AI, AR enhancement, and infrared. With the implementation of these products, the company's performance is expected to continue to achieve high growth, creating substantial returns for investors.